

NEUROSCIENTIFIC GRANTED ETHICS APPROVAL FOR EARLY-PHASE CLINICAL TRIAL

HIGHLIGHTS

- **Ethics approval received for an early-phase clinical trial of EmtinB™ in up to 30 healthy volunteers**
- **HREC approval is a significant milestone for NeuroScientific in progressing EmtinB™ towards the landmark achievement of commencing clinical development in 1H 2022**
- **The early-phase clinical trial will include biomarker studies to assess proof of mechanism activity of EmtinB™ and guide efficacy outcomes in future clinical trials in patients**
- **Clinical trial activities are expected to commence immediately, including recruitment of subjects**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the company**”) is pleased to announce the Company has received approval from the Human Research Ethics Committee (HREC) for its early-phase clinical trial of lead drug candidate EmtinB™ which will be undertaken by leading WA-based clinical research partner Linear Clinical Research. HREC approval for the clinical trial is a significant milestone for NeuroScientific in achieving the landmark outcome of commencing its first clinical trial in 1H 2022.

The early-phase clinical trial will include up to 30 healthy volunteers with recruitment of subjects expected to start immediately. An important focus of this study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB™ in humans and can be used to guide efficacy outcomes during future trials in patients.

NeuroScientific’s Managing Director and Chief Executive Officer Matt Liddelow commented: “*The commencement of the clinical development program for EmtinB™ is a significant milestone in progressing our lead drug candidate towards commercialisation and is a historic accomplishment for the Company, being the first clinical trial to be initiated by NeuroScientific.*”

This clinical trial forms the initial part of our clinical development strategy for EmtinB™ as a potential disease-modifying treatment for neurodegenerative conditions, such as our lead indications Alzheimer’s disease and Multiple sclerosis.

I look forward to providing further updates on the commencement of clinical trial activities during the coming weeks.”

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS

For more information please contact:

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatetorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Early-Phase / Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.